OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.540
-0.030 (-1.91%)
At close: Dec 20, 2024, 4:00 PM
1.560
+0.020 (1.30%)
After-hours: Dec 20, 2024, 5:43 PM EST
OPKO Health Revenue
OPKO Health had revenue of $173.63M in the quarter ending September 30, 2024, a decrease of -2.78%. This brings the company's revenue in the last twelve months to $711.41M, down -17.94% year-over-year. In the year 2023, OPKO Health had annual revenue of $863.50M, down -14.01%.
Revenue (ttm)
$711.41M
Revenue Growth
-17.94%
P/S Ratio
1.54
Revenue / Employee
$181,020
Employees
3,930
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 863.50M | -140.70M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | 901.94M | -88.33M | -8.92% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 812.04M |
| ANI Pharmaceuticals | 555.46M |
| Establishment Labs Holdings | 153.07M |
| Bicycle Therapeutics | 36.90M |
| Syndax Pharmaceuticals | 16.00M |
| ARS Pharmaceuticals | 2.57M |
OPK News
- 4 weeks ago - NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo - PRNewsWire
- 5 weeks ago - NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results - PRNewsWire
- 6 weeks ago - OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program - GlobeNewsWire
- 2 months ago - NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan - PRNewsWire
- 3 months ago - Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health - PRNewsWire
- 4 months ago - OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results - GlobeNewsWire
- 5 months ago - OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments - GlobeNewsWire